Business Description
Tanvex BioPharma Inc
NAICS : 541713
SIC : 2833
ISIN : KYG8676P1037
Total Employee Number:
201Compare
Compare
Traded in other countries / regions
6541.Taiwan Index Membership
TSEC Weighted IndexTSEC Weighted IndexTSEC Weighted Index IPO Date
2015-08-13Description
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company operates in Asia, America, Europe, and Australia. The company generates a majority of its revenue from the USA.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.56 | |||||
Equity-to-Asset | 0.72 | |||||
Debt-to-Equity | 0.28 | |||||
Debt-to-EBITDA | -1.45 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -0.29 | |||||
Beneish M-Score | 17.7 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 106.1 | |||||
3-Year EBITDA Growth Rate | 25.8 | |||||
3-Year EPS without NRI Growth Rate | 23.6 | |||||
3-Year FCF Growth Rate | 16.9 | |||||
3-Year Book Growth Rate | 23.6 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 58.05 | |||||
9-Day RSI | 54.12 | |||||
14-Day RSI | 53.12 | |||||
3-1 Month Momentum % | -1.43 | |||||
6-1 Month Momentum % | -25.32 | |||||
12-1 Month Momentum % | -24.01 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.87 | |||||
Quick Ratio | 1.35 | |||||
Cash Ratio | 1.1 | |||||
Days Inventory | 139.05 | |||||
Days Sales Outstanding | 62.33 | |||||
Days Payable | 18.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -29.4 | |||||
Shareholder Yield % | -9.84 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -109.91 | |||||
Operating Margin % | -344.59 | |||||
Net Margin % | -374.13 | |||||
EBITDA Margin % | -271.65 | |||||
FCF Margin % | -417.9 | |||||
OCF Margin % | -250.75 | |||||
ROE % | -32.59 | |||||
ROA % | -22.44 | |||||
ROIC % | -24.81 | |||||
3-Year ROIIC % | 5.37 | |||||
ROC (Joel Greenblatt) % | -61 | |||||
ROCE % | -23.86 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 26.07 | |||||
PB Ratio | 1.93 | |||||
Price-to-Tangible-Book | 4.77 | |||||
EV-to-EBIT | -8.02 | |||||
EV-to-EBITDA | -10.71 | |||||
EV-to-Revenue | 29.1 | |||||
EV-to-FCF | -6.96 | |||||
Price-to-GF-Value | 0.16 | |||||
Earnings Yield (Greenblatt) % | -12.47 | |||||
FCF Yield % | -15.27 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tanvex BioPharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 400.971 | ||
| EPS (TTM) (NT$) | -6.181 | ||
| Beta | -0.0732 | ||
| 3-Year Sharpe Ratio | -0.46 | ||
| 3-Year Sortino Ratio | -0.68 | ||
| Volatility % | 22.95 | ||
| 14-Day RSI | 53.12 | ||
| 14-Day ATR (NT$) | 1.783664 | ||
| 20-Day SMA (NT$) | 40.835 | ||
| 12-1 Month Momentum % | -24.01 | ||
| 52-Week Range (NT$) | 37.3 - 68 | ||
| Shares Outstanding (Mil) | 264.99 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tanvex BioPharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tanvex BioPharma Inc Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| 0.333577:1 Stock Split | 2023-03-02 | 107.37 (-0.67%) |
Show
Entries
Tanvex BioPharma Inc Frequently Asked Questions
What is Tanvex BioPharma Inc(TPE:6541)'s stock price today?
The current price of TPE:6541 is NT$41.40. The 52 week high of TPE:6541 is NT$68.00 and 52 week low is NT$37.30.
When is next earnings date of Tanvex BioPharma Inc(TPE:6541)?
The next earnings date of Tanvex BioPharma Inc(TPE:6541) is .
Does Tanvex BioPharma Inc(TPE:6541) pay dividends? If so, how much?
Tanvex BioPharma Inc(TPE:6541) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Tanvex BioPharma Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers